The Role of Dynamic Positron Emission Tomography for Quantifying Boron-10 in Vivo Using the Fructose Complex of Fluorine-18 Labeled Boronophenylalanine
One of the major difficulties facing successful boron neutron capture therapy (BNCT) is the paucity of in vivo pharmacokinetic data.1 Analytical techniques such as prompt gamma analysis, secondary ion mass spectrometry, and resonance ionization spectroscopy are simply not applicable to the in vivo detection of boron.2 To address this problem, both positron emission tomography (PET)3,4 and magnetic resonance imaging (MRI)5 techniques for the in vivo detection of boronated compounds are being developed. Nuclear medicine diagnostic techniques such as PET have proven to be extremely valuable in evaluating a variety of physiological parameters including the pharmacokinetic behavior of therapeutic agents.6,7,8 In fact, over nine thousand patients have been evaluated at The University of Tennessee utilizing PET since 1989.
KeywordsArthritis Boron Sarcoma Resid Fructose
Unable to display preview. Download preview PDF.
- 8.E. Buonocore, K. Hubner, J. Collman, and G.W. Kabalka, Clinical Positron Emission Tomgraphy, Mosby Yearbook, Hanover, MD, 1991.Google Scholar
- 11.J.P. Pignol, H. Oudart, P. Chauvel, W. Sauerwein, D. Gabel, and G. Prevot, Selective Delivery of ,10B to Soft Tissue Sarcoma Using 10B-L-Borophenylalanine for Boron Neutron Capture Therapy, Br. J. Radiol., 843:320, 1998.Google Scholar
- 12.R.A. Watson-Clark, M.L. Banquerigo, K. Shelly, M.F. Hawthorne, and E. Brahn, Model Studies Directed Toward the Application of Boron Neutron Capture Therapy to Rheumatoid Arthritis: Boron Delivery by Liposomes in Rat Collagen-Induced Arthritis, Proc. Natl. Acad. Sci. U.S.A., 95:2531, 1998.PubMedCrossRefGoogle Scholar